Clinical Trials Logo
  1. Home
  2. Other
  3. NCT06051513

Efficacy and Safety of Colistimethate Sodium for Injection in The Treatment of Carbapenem-Resistant Enterobacteriaceae Infection

Carbapenem-Resistant Enterobacteriaceae Infection Clinical Trial

Official title:
Colistimethate Sodium for Injection in The Treatment of Carbapenem-Resistant Enterobacteriaceae Infection：a Prospective, Open-label, Randomized Controlled, Multicenter Clinical Trial

Clinical Trial Summary

Colistin can be used to treat the infection caused by carbapenem-resistant enterobacteriaceae(CRE). In China, patients diagnosed with Hospital-acquired-pneumonia (HAP)or bloodstream infection caused by CRE are recruited, and randomly assigned to two groups, and in one group the patients accept treatment with colistin, however in another group, the patients accept treatment without colistin. The efficacy and safety of the treatment between the two groups are compared.

Clinical Trial Description

The study will be conducted in accordance with good clinical practice and with the guidelines set out in the Declaration of Helsinki. After approval from local and national ethics committees, patients diagnosed with Hospital-acquired-pneumonia (HAP)or bloodstream infection caused by CRE from 14 centres in China will be recruited. All patients will be randomized to receive treatment with or without colistin in the ICU. The purpose of this study is to investigate the efficacy and safety of colistin when used to treat patients with CRE infection. The primary outcome is 14-day all cause mortality and the second outcomes include 14-day clinical cure rate, 14-day efficacy rate, ICU free days within 28 days after randomization，14-day microbiological cure rate，incidence of adverse events and severe adverse events in first 14 days, hospital mortality, 28-day all cause mortality, ICU mortality. Clopper-Pearson method is used to calculate the 95% confidence interval of mortality, Miettinen and Nurminen method is used to detect the difference between the two groups. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT06051513
Study type Interventional
Source Southeast University, China
Contact Yingzi Huang, MD
Phone +86-025-83262552
Email yz_huang@126.com
Status Recruiting
Phase N/A
Start date September 21, 2023
Completion date November 30, 2025
View Details
See also
  Status Clinical Trial Phase
Not yet recruiting NCT04516395 - Optimizing Antibiotic Dosing Regimens for the Treatment of Infection Caused by Carbapenem Resistant Enterobacteriaceae N/A
Completed NCT04146337 - Fecal Microbiota Transplantation for Carbapenem-resistant Enterobacteriaceae Phase 2/Phase 3
Completed NCT04167228 - Impact of Ceftazidime / Avibactam Treatment vs Better Available Therapy on Mortality of Patients With Infections Caused by Carbapenem-resistant Enterobacteria
Terminated NCT04876430 - Best Available Therapy With or Without Meropenem for Bloodstream Infections by Enterobacterales With High Level of Resistance to Carbapenems Phase 2/Phase 3
Enrolling by invitation NCT03924934 - Community-associated Highly-Resistant Enterobacterales
Recruiting NCT04583098 - The Effect of Fecal Microbiota Transplantation on the Decolonization of Multidrug-resistant Organisms
Recruiting NCT04535661 - Risk Factors for Colonization or Infection With Carbapenem-Resistant Enterobacteriaceae in Children
Withdrawn NCT04785924 - Imipenem/Cilastatin/Relebactam (IMI/REL) in Treatment of CRE Infections Phase 4
Terminated NCT05258851 - Ceftazidime-Avibactam Use in Critically Ill Patients With Carbapenem-Resistant Enterobacteriaceae Infections Phase 3
Not yet recruiting NCT04746222 - Oral Capsule Faecal Microbiota Transplantation for CPE Decolonization Phase 2/Phase 3
Recruiting NCT04014413 - Safety and Efficacy of Fecal Microbiota Transplantation N/A
Recruiting NCT05871476 - Interventions to Decrease CRE Colonization and Transmission Between Hospitals, Households, Communities and Domesticated Animals N/A
Recruiting NCT05850871 - Drug Resistance Mechanism of Enterobacteriaceae and Its Strategies N/A
Terminated NCT05210387 - Seven Versus 14 Days of Antibiotic Therapy for Multidrug-resistant Gram-negative Bacilli Infections N/A
Not yet recruiting NCT06210542 - Precise Treatment of Ceftazidime-Avibactam in Patients With CRO Infections Under the Guidance of TDM and PPK Model
Not yet recruiting NCT05981430 - Fecal Microbiota Transplantation for Decolonization of Carbapenem-resistant Enterobacteriaceae N/A
Recruiting NCT06258551 - Dynamics of Colonization and Infection by Multidrug-Resistant Pathogens in Immunocompromised and Critically Ill Patients
Recruiting NCT05979545 - EaRly impAct theraPy With Ceftazidime-avibactam Via rapID Diagnostics Phase 4
Completed NCT04790565 - Fecal Microbiota Transplantation for Carbapenem Resistant Enterobacteriaceae Phase 2/Phase 3